热门资讯> 正文

阿斯利康完成对Fusion Pharmaceuticals的收购

2024-06-05 05:19

阿斯利康(AZN) 0
Fusion Pharmaceuticals(FUSN) 0

AstraZeneca has completed its $2B acquisition of Fusion Pharmaceuticals.
Late last month, Fusion shareholders overwhelmingly approved the deal.
Fusion is focused on the development of radiopharmaceuticals to treat cancer. Its lead program, FPI-2265, is in phase 2 for metastatic castration resistant prostate cancer.

More on AstraZeneca

AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath
AstraZeneca: A Triple Shot Of Income, Growth, And Value
AstraZeneca: Strong In A Weak Market
AstraZeneca reports positive data for Tagrisso, Imfinzi, Enhertu
Emerging and Chinese pharmas playing greater role in oncology drug development

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。